Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, Violeta Serra et al.|Nature Communications|2024Cited by 23
Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)Mafalda Oliveira, Aleix Prat, Tomás Pascual et al.|Clinical Cancer Research|2025Cited by 3
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancerSilvana Mourón, Miguel Quintela-Fandiño, María J. Bueno et al.|JNCI Cancer Spectrum|2023Cited by 2
Abstract OT2-19-08: Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6Luís Manso, Miguel Quintela-Fandiño, Alfonso Cortés et al.|Cancer Research|2022Cited by 1
Abstract PS12-07: Phase II clinical trial of palbociclib and binimetinib in advanced triple-negative breast cancer (TNBC) with hyperactivation of ERK and/or CDK4/6Rodrigo Sánchez-Bayona, Miguel Quintela-Fandiño, Alfonso Cortés et al.|Cancer Research|2024Cited by 0